Page 108 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Figure 6. Followup frequencies of 13 unique cohorts of observational management strategies with
a
palliative intent (continued)
Year 1 2 3 4 5
1 1 1 2 2 2 3 3 3 3 4 4 4 5 5 5 6
WW cohort Month 3 6 9 2 5 8 1 4 7 0 3 6 9 2 5 8 1 4 7 0
Hospitals in
Manchester
region 148 PSA √ √ √ √ √ √ √ √ √ √
DRE
b
Bone scan Probably not routine
University of
Florida 149 PSA √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
DRE √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Rebiopsy √
Legends: √* = every 3 mo for the first 5 yr; every 4-6 mo thereafter; √** = usually every 6 mo but followup regimens varied
among local practices. Merged cell represents a range of followup frequency; for example, a merged cell of 3 and 6 mo with a
check mark in the middle of the merged cell means a followup frequency of 3 to 6 mo. PAP = prostate acid phosphatase
HUCM = Howard University College of Medicine; Northern Stockholm = Northern Stockholm region in UK; SPCG-4 =
Scandinavian Prostate Cancer Group Study Number 4 trial; PIVOT= Prostate Cancer Intervention Versus Observation Trial;
Hospitals in Manchester region= University Hospital of South Manchester, Withington Hospital, Christie Hospital; Hope
Hospital
a Cohorts of watchful waiting in chronological order of starting enrollment year. See Table 8 for more detailed monitoring
criteria in each cohort.
b The authors reported that all patients underwent “multiple bone scans” during followup and all had normal findings.

57